Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT03872232
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT03872232
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03872232. Randomized; quadruple masking; primary purpose treatment. Start 2019-02-26 (actual); primary completion 2020-08-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
- Condition
- Hypercholesterolemia
- Condition
- Hypertension
- Intervention (Drug)
- Ezetimibe/Rosuvastatin
- Intervention (Drug)
- Telmisartan
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct03872232- Content hash
0ae3c78fb894cbf2ff912e50a93f682442e62093d0d72506b41dd0b6a2d25768